Bvf Partners L. P/Il Sells 392,723 Shares of XOMA Co. (NASDAQ:XOMA) Stock

XOMA Co. (NASDAQ:XOMA) major shareholder Bvf Partners L. P/Il sold 392,723 shares of the business’s stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $27.10, for a total value of $10,642,793.30. Following the completion of the transaction, the insider now owns 1,267,545 shares of the company’s stock, valued at $34,350,469.50. This represents a 23.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

XOMA Trading Down 5.6%

NASDAQ XOMA opened at $25.12 on Thursday. XOMA Co. has a 52 week low of $18.35 and a 52 week high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The stock’s 50 day moving average price is $22.35 and its two-hundred day moving average price is $25.39. The stock has a market capitalization of $300.61 million, a price-to-earnings ratio of -7.22 and a beta of 0.89.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.32. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The company had revenue of $15.91 million for the quarter, compared to the consensus estimate of $6.75 million. As a group, analysts anticipate that XOMA Co. will post -1.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on XOMA shares. HC Wainwright reaffirmed a “buy” rating and issued a $104.00 price target on shares of XOMA in a research note on Friday, March 28th. Benchmark started coverage on XOMA in a report on Thursday, April 17th. They set a “buy” rating and a $35.00 target price for the company. Finally, StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research note on Friday, April 11th.

Institutional Investors Weigh In On XOMA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its stake in shares of XOMA by 1,063.8% during the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,585 shares during the last quarter. New York State Common Retirement Fund raised its holdings in XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 800 shares in the last quarter. Wells Fargo & Company MN raised its holdings in XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 1,183 shares in the last quarter. Deutsche Bank AG boosted its position in XOMA by 5,087.9% during the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 6,309 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in XOMA by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 2,009 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.